CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public ...

The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a new evaluation tool.

Exelixis delivers a strong Q1 performance with raised 2025 guidance, robust Cabometyx sales, and share buybacks. Read the ...

Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen ...

Revisions to classification criteria ‘will ensure homogeneous trial populations’ with data-driven scoring, a standardized MRI ...

The risk calculator shows improved precision in a population larger than the original dataset used to validate the tool.

Bristol-Myers Squibb is getting the corporate equivalent of a polite shrug from analysts, with most advising investors to ...

We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now. In this article, we are ...

Buried in a technical document released by the Centers for Medicare and Medicaid Services is a convoluted paragraph that may ...

Analysts are still crunching the numbers on the impact of President Donald Trump's executive order from Monday on drug pricing. HSBC analyst Rajesh Kumar says a 20% price cut in government channels ...